- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | GH Research GAAP EPS of -$0.15 | 1 | Seeking Alpha | ||
| 01.08. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | JMP reiterates Market Outperform rating on GH Research stock at $39 target | 5 | Investing.com | ||
| 23.07. | GH Research reports progress on FDA engagement for GH001 IND | 1 | Investing.com | ||
| 23.07. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | GH Research PLC: GH Research Announces Global Pivotal Program Plans and Further Development Updates | 192 | GlobeNewswire (Europe) | Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment... ► Artikel lesen | |
| GH RESEARCH Aktie jetzt für 0€ handeln | |||||
| 10.07. | GH Research stock awaits FDA response on clinical hold, says Canaccord | 1 | Investing.com | ||
| 09.07. | GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule | 2 | Insider Monkey | ||
| 24.06. | JMP bekräftigt Bewertung für GH Research nach positiven Ergebnissen eines Konkurrenten | - | Investing.com Deutsch | ||
| 24.06. | JMP reiterates GH Research stock rating on competitor's positive results | 1 | Investing.com | ||
| 20.06. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.06. | GH Research reicht Antwort auf FDA-Klinische Sperre für Depressionsmedikament ein | 2 | Investing.com Deutsch | ||
| 20.06. | GH Research submits response to FDA clinical hold for depression drug | 2 | Investing.com | ||
| 20.06. | GH Research PLC: GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule | 170 | GlobeNewswire (Europe) | DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 13.06. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.06. | Cantor Fitzgerald behält Übergewichtung für GH Research-Aktie bei | 2 | Investing.com Deutsch | ||
| 27.05. | GH Research PLC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 15.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.05. | GH Research PLC: GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting | 79 | GlobeNewswire (Europe) | DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing... ► Artikel lesen | |
| 08.05. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,580 | +0,09 % | EQS-News: Evotec SE: Bekanntgabe der Ergebnisse für das erste Halbjahr 2025 am 13. August 2025 | EQS-News: Evotec SE
/ Schlagwort(e): Halbjahresergebnis
Evotec SE: Bekanntgabe der Ergebnisse für das erste Halbjahr 2025 am 13. August 2025
06.08.2025 / 09:52 CET/CEST
Für... ► Artikel lesen | |
| VALNEVA | 3,982 | +0,20 % | Valneva: FDA gibt Chikungunya-Impfstoff IXCHIQ wieder frei | Valneva hat bekanntgegeben, dass die US-Arzneimittelbehörde FDA die zuvor empfohlene Einschränkung für den Chikungunya-Impfstoff IXCHIQ bei Personen ab 60 Jahren aufgehoben hat. Zugleich wurde eine... ► Artikel lesen | |
| BIOFRONTERA | 2,700 | -1,82 % | A Look at Biofrontera's Upcoming Earnings Report | ||
| BIOGEN | 110,60 | +0,18 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome | - Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period -
- Dravet syndrome is a rare genetic disease characterized by... ► Artikel lesen | |
| ILLUMINA | 82,79 | -0,77 % | Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit | ||
| NANOREPRO | 1,565 | -3,10 % | EQS-News: GBC AG: EINLADUNG ZUM GBC INVESTORS CALL - NanoRepro AG | EQS-News: GBC AG
/ Schlagwort(e): Jahresbericht
EINLADUNG ZUM GBC INVESTORS CALL - NanoRepro AG
12.08.2025 / 10:15 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| OCUGEN | 0,884 | +0,32 % | Ocugen schließt Kapitalerhöhung über 20 Millionen US-Dollar mit Janus Henderson ab | ||
| VAXART | 0,293 | -4,00 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders | - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart,... ► Artikel lesen | |
| CYTODYN | 0,196 | -11,71 % | CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab | Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal... ► Artikel lesen | |
| IMMUNIC | 0,712 | -2,20 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07.08.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| CEL-SCI | 7,470 | 0,00 % | CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer | Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,015 | +1,61 % | Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday | ||
| MUSTGROW BIOLOGICS | 0,423 | +1,93 % | MustGrow Biologics Corp.: MustGrow Announces Non-Brokered LIFE Offering of up to $3 Million, Proposed Repricing of Warrants, and Shares for Debt Settlement Offer to Debentureholders | Saskatoon, Saskatchewan--(Newsfile Corp. - July 30, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the following: (i)... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Issues Stockholder Letter and Provides 2025 Corporate Update | Company Achieves Multiple Clinical Development Milestones in 2025
Patient Treatment Continues in Two Lung Cancer Clinical Trials
AUSTIN, Texas, Aug. 4, 2025 ... ► Artikel lesen | |
| AMICUS THERAPEUTICS | 6,000 | 0,00 % | Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates | Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including... ► Artikel lesen |
Das Unternehmen GH RESEARCH PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,500 Euro und damit -2,78 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GH RESEARCH PLC finden Sie auf Wallstreet Online.